Insurance Denied Genetic Counseling or BRCA Testing: How to Appeal

Genetic counseling and hereditary cancer testing — including BRCA1/BRCA2 gene testing and Lynch syndrome panels — can identify life-threatening cancer risks years before cancer develops. When insurers deny these services, they are withholding coverage for some of the highest-value preventive medicine available. For many patients, a denied genetic test means a missed window for risk-reducing surgery, enhanced surveillance, or chemoprevention. These denials are often legally and clinically indefensible.

Why Insurers Deny Genetic Counseling and Testing

• Not medically necessary: The insurer argues the patient does not meet its internal criteria for genetic counseling or testing, often applying criteria more restrictive than USPSTF Grade B recommendations
• Preventive vs. diagnostic coding dispute: Testing for high-risk patients may be classified as diagnostic, triggering cost-sharing even when USPSTF-recommended testing should be covered at no cost under ACA Section 2713
• Hereditary cancer panel classified as "not medically necessary": Insurers may approve single-gene testing while denying multi-gene panels, even when a panel is the clinically appropriate and cost-effective approach
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not obtained: Genetic testing, particularly multigene panels, requires prior authorization from most insurers; missing auth results in denial regardless of clinical appropriateness
• Out-of-network laboratory: Many genetic testing laboratories are out of network, creating coverage disputes even when the test itself is covered

Under the Genetic Information Nondiscrimination Act (GINA) of 2008, health insurers cannot use genetic information to deny coverage or charge higher premiums — fear of discrimination should never deter you from seeking or appealing genetic testing coverage.

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered service), CO-197 (prior authorization required), CO-4 (diagnosis inconsistent with procedure).

How to Appeal a Genetic Counseling or Testing Denial

Step 1: Determine Whether ACA Zero Cost-Sharing Applies

The USPSTF issued a Grade B recommendation in 2019 for women with personal or family history suggesting hereditary BRCA-related cancer risk to be referred for genetic counseling and, if indicated, BRCA testing. Under ACA Section 2713, Grade B USPSTF recommendations must be covered without cost-sharing by non-grandfathered plans. USPSTF qualifying criteria include: first-degree relative with BRCA1/2 mutation; multiple family members with breast or ovarian cancer; breast cancer before age 50; triple-negative breast cancer; bilateral breast cancer; male breast cancer; Ashkenazi Jewish ancestry with cancer in a relative. If your testing qualifies under USPSTF criteria, the denial may be an ACA violation, not just a medical necessity dispute.

Step 2: Document Your Risk Factors Systematically

A family history letter from your physician or genetic counselor should systematically list all relevant cancer diagnoses in your family (cancer type, age at diagnosis, relationship to patient), personal cancer history, Ashkenazi Jewish or other high-risk ancestry, and the specific USPSTF or NCCN criterion you meet. For women of Ashkenazi Jewish descent, the frequency of BRCA1/2 founder mutations (approximately 1 in 40 individuals) is substantially higher than the general population — cite this as an independent risk factor.

Step 3: Compare Insurer Criteria to NCCN Guidelines

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines provide broader genetic testing criteria than many insurers apply. NCCN criteria for BRCA testing cover: early-onset breast cancer (before age 50); triple-negative breast cancer; ovarian cancer; and Ashkenazi Jewish ancestry with breast or ovarian cancer in a relative. For Lynch syndrome: Amsterdam II criteria, revised Bethesda guidelines, or mismatch repair deficiency on tumor testing. If the insurer's criteria are more restrictive than NCCN guidelines, document this discrepancy explicitly and cite the specific NCCN criteria your case meets. NCCN guidelines are available at nccn.org with free registration.

Step 4: Invoke ACA Section 2713 for BRCA Testing

For qualifying patients, write formally that ACA Section 2713 requires non-grandfathered plans to cover USPSTF Grade B preventive services without cost-sharing. Request that the insurer provide a written explanation of how they are complying with this mandate and address whether they are applying it correctly to your case.

Step 5: Challenge "Investigational" Classifications for Multi-Gene Panels

Multi-gene hereditary cancer panels testing 25–80 genes simultaneously are standard practice at major cancer centers and endorsed by NCCN, the American College of Medical Genetics and Genomics (ACMG), and the American Society of Clinical Oncology (ASCO). Cite NCCN and ACMG standards supporting panel testing for your indication and note that panels are recommended when a single-gene test is indicated and the panel adds clinical value by identifying additional actionable variants.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review

Genetic testing denials that conflict with NCCN guidelines or USPSTF recommendations are frequently overturned on external review. Request a reviewer with genetics or oncology expertise.

What to Include in Your Appeal

• Family history summary: Cancer diagnoses, ages at diagnosis, and relationships — ideally in pedigree format
• USPSTF 2019 Grade B recommendation: For BRCA testing in qualifying patients, with specific qualifying criterion your case meets
• NCCN genetic testing criteria: Specific section applicable to your cancer syndrome and family history
• ACOG Committee Opinion 727: For hereditary breast-ovarian cancer syndrome (HBOC) if applicable
• ACA Section 2713 citation: For cases where zero cost-sharing should apply under the ACA preventive care mandate

Fight Back With ClaimBack

Genetic counseling and BRCA testing denials are among the most consequential insurance decisions a patient faces — a missed diagnosis can cost a life. When testing criteria under USPSTF or NCCN guidelines are met, these denials are legally and clinically indefensible. ClaimBack helps you document your risk factors, cite the right guidelines and federal law, and build an appeal that forces your insurer to reconsider. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal